Table 1.
Parameters used in simulationa
| Probability of achieving Hit to Lead milestone | 0.80 |
|---|---|
| Probability of achieving Lead Optimization milestone |
0.75 |
| Probability of achieving Preclinical Development milestone |
0.85 |
| Percentage of follow-on Hit to Lead projects |
0.25 |
| Percentage of chemistry-driven Hit to Lead projects |
0.5 |
| Percentage of prioritized Lead Optimization projects |
0 |
| Target no. Hit to Lead CHEMISTS (chemistry-driven) per team |
2 |
| Target no. Hit to Lead BIOLOGISTS (chemistry-driven) per team |
3 |
| Target no. Hit to Lead CHEMISTS (biology-driven) per team |
1 |
| Target no. Hit to Lead BIOLOGISTS (biology-driven) per team |
3 |
| Target no. Hit to Lead CHEMISTS (follow-on) per team |
2 |
| Target no. Hit to Lead BIOLOGISTS (follow-on) per team |
1 |
| Target no. Lead Optimization CHEMISTS per team |
4 |
| Target no. Lead Optimization BIOLOGISTS per team |
4 |
| No. simultaneous Lead Optimization projects supported by DMPK |
0 |
| Percent impact on timeline by DMPK support |
0.1 |
| Target cycle time (months) to achieve Lead Optimization |
18 |
| Target cycle time (months) to achieve Preclinical Development |
24 |
| Group size at 75% FTE efficiency |
20 |
| Group size at 50% FTE efficiency | 40 |
aSee Experimental section for a detailed explanation of the control variables.